Home › Funds › Deep Track Capital, LP › GPCR
Deep Track Capital, LP position in GPCR
STRUCTURE THERAPEUTICS INC · Health Care
Deep Track Capital, LP reported holding 5,000,000 shares of GPCR (STRUCTURE THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$156.3M, representing 2.61% of its reported portfolio and ranking #11 among its reported holdings. Deep Track Capital, LP has disclosed GPCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Deep Track Capital, LP's GPCR position evolved
Deep Track Capital, LP first disclosed a stake in GPCR in Q3 2023 at 1,915,000 shares (US$96.6M). The position peaked in Q4 2025 at 4,111,782 shares, worth US$286.0M. Across 13 filings, Deep Track Capital, LP increased the stake 8 time(s), trimmed it 4 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 5,000,000 shares valued at US$156.3M — an increase of 259,928 shares quarter over quarter.. Notable position changes include a 87% trim in Q1 2024 (shares fell 8% over the following quarter), a 2267% increase in Q2 2024 (shares rose 12% over the following quarter), a 129% increase in Q4 2024 (shares fell 36% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 1.92M | $96.55M | New |
| Q4 2023 | 300.00K | $12.23M | Reduce |
| Q1 2024 | 40.14K | $1.72M | Reduce |
| Q2 2024 | 950.00K | $37.31M | Add |
| Q3 2024 | 1.22M | $53.57M | Add |
| Q4 2024 | 2.80M | $75.94M | Add |
| Q1 2025 | 4.10M | $70.97M | Add |
| Q2 2025 | 5.13M | $106.48M | Add |
| Q3 2025 | 4.22M | $118.04M | Reduce |
| Q4 2025 | 4.11M | $285.97M | Reduce |
| Q1 2026 | 4.28M | $206.29M | Add |
| Q2 2026 | 4.74M | $254.40M | Add |
| Q3 2026 | 5.00M | $156.35M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GPCR and 13F data
GPCR (STRUCTURE THERAPEUTICS INC) is a Health Care company. 25 other funds we track also report a position in GPCR — the largest reported positions include Avoro Capital Advisors LLC (US$205.0M), BVF INC/IL (US$180.7M), ORBIMED ADVISORS LLC (US$118.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GPCR
- Avoro Capital Advisors LLC 6.56M sh · $204.99M · Q3 2026
- BVF INC/IL 3.37M sh · $180.70M · Q2 2026
- ORBIMED ADVISORS LLC 2.21M sh · $118.58M · Q2 2026
- BAKER BROS. ADVISORS LP 1.43M sh · $76.88M · Q2 2026
- RTW INVESTMENTS, LP 2.28M sh · $71.36M · Q3 2026
- Casdin Capital 1.18M sh · $63.06M · Q2 2026
- DEERFIELD MANAGEMENT COMPANY, L.P. 1.09M sh · $58.29M · Q2 2026
- Paradigm Biocapital Advisors LP 1.30M sh · $40.63M · Q3 2026
- Logos Global Management LP 1.00M sh · $31.27M · Q3 2026
- Siren, L.L.C. 872.97K sh · $27.30M · Q3 2026
- PACIFIC HEIGHTS ASSET MANAGEMENT LLC 800.00K sh · $25.02M · Q3 2026
- Rock Springs Capital Management LP 640.32K sh · $20.02M · Q3 2026
More on Deep Track Capital, LP
FAQ
How long has Deep Track Capital, LP held GPCR?
Deep Track Capital, LP has disclosed GPCR holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is Deep Track Capital, LP's current position in GPCR?
As of Q3 2026, Deep Track Capital, LP holds 5.00M shares of GPCR (STRUCTURE THERAPEUTICS INC), valued at $156.35M, representing 2.61% of its reported portfolio and ranking #11.
Has Deep Track Capital, LP been buying or selling GPCR?
In the latest 13F filing (Q3 2026), Deep Track Capital, LP increased its position in GPCR. The position peaked in Q4 2025 at 4.11M shares.
Which other funds hold GPCR?
Other major institutional holders of GPCR include Avoro Capital Advisors LLC, BVF INC/IL, ORBIMED ADVISORS LLC, among 25 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.